Sarepta Therapeutics (NasdaqGS:SRPT) saw its share price rise by 19% over the past month, a move that notably outpaced the broader market's 1% increase for the week and the 13% gain over the year.

FY25 performance impressed with strong Commerce & Fintech growth, but short-term risks and valuation concerns suggest a 'hold ...

Blue Owl Capital's high permanent capital base and strong fee growth should support consistent earnings across market cycles.

You can buy stocks during a downturn because, by holding on for five years or more, you're giving those companies time to ...

Small-cap stocks haven’t been this cheap in decades. This valuation advantage gets interesting when we add big fat dividends.